NUSNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
NU SKIN ENTERPRISES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$4.97−0.17 (-3.31%)
Close on Oct 19, 2026
- Market cap
- $241.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
69.4%−5.1 pts over 5 years
Operating margin
4.4%−5.5 pts over 5 years
Net margin
10.8%+3.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.3% | -12.6% | -10.5% | -4.1% | |
| Gross profit | -12.7% | -13.5% | -11.7% | -5.2% | |
| Operating income | – | -16.0% | -23.9% | -12.3% | |
| Net income | – | +15.2% | -3.5% | +1.9% | |
| EPS, diluted | – | +15.4% | -2.6% | +3.5% | |
| Free cash flow | -34.4% | -2.1% | -32.0% | -16.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 19.2% | 21.6% | 22.0% | |
| Return on assets | 9.6% | 10.3% | 11.1% | |
| Current ratio | 1.79 | 1.66 | 2.08 | |
| Debt to equity | 0.63 | 0.38 | 0.28 | |
| Net debt to EBITDA | 0.20× | -0.20× | -0.12× | |
| Interest coverage | 14.8× | 19.7× | 4.7× | |
| Inventory turnover | 1.9× | 2.2× | 2.5× | |
| Capex to revenue | 2.3% | 2.5% | 2.3% | |
| Diluted shares | 56M | 53M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nu Skin Enterprises generated $560.31M from operations and spent $700.21M on capital expenditure, dividends and share buybacks. 37% of that went back into the business.
Generated
$560.31M
Used
$700.21M
Capital expenditure$262.02M37%Dividends$254.67M36%Share buybacks$183.52M26%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin10.8%
×Asset turnover1.03×
×Equity multiplier1.97×
=Return on equity, FY202522.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 10.8% | 1.03× | 1.97× | 22.0% |
| FY2024 | -8.5% | 1.06× | 2.22× | -19.9% |
| FY2023 | 0.4% | 1.09× | 2.11× | 1.0% |
| FY2022 | 4.7% | 1.19× | 2.06× | 11.6% |
| FY2021 | 5.5% | 1.40× | 2.14× | 16.3% |
| FY2020 | 7.4% | 1.39× | 2.11× | 21.6% |
| FY2019 | 7.2% | 1.40× | 2.09× | 20.9% |
| FY2018 | 4.5% | 1.63× | 2.21× | 16.4% |
| FY2017 | 5.7% | 1.49× | 2.24× | 18.9% |
| FY2016 | 6.5% | 1.48× | 2.00× | 19.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$160.20M
- Cash generatingOperating cash flow above zero$80.29M
- Return on assets improvedROA up on the prior year-8.1% → 10.9%
- Earnings backed by cashOperating cash flow above net income$80.29M vs $160.20M
- Less leverageLong-term debt to assets fell24.8% → 14.5%
- Better liquidityCurrent ratio rose1.82 → 2.08
- No dilutionShare count did not rise50M → 50M
- Gross margin improvedGross margin up on the prior year68.23% → 69.45%
- More efficientAsset turnover rose0.96 → 1.01